celecoxib has been researched along with Dermatoses in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of Celecoxib decreased DON-induced translocation of Protein Kinase C isozymes (α,ε,γ), demonstrating the role of PKC in DON-mediated biochemical and molecular alterations responsible for its dermal toxicity." | 5.56 | Celecoxib reduces Deoxynivalenol induced proliferation, inflammation and protein kinase C translocation via modulating downstream targets in mouse skin. ( Chaturvedi, S; Dewangan, J; Divakar, A; Kumar, S; Mandal, P; Mishra, S; Rath, SK; Srivastava, S; Tripathi, A; Wahajuddin, M, 2020) |
| " The main toxicities were grades 1 and 2 nausea and esophagitis, and they were independent of the dose of celecoxib or radiotherapy schedule." | 5.11 | A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. ( Blumenschien, G; Brown, B; Chang, JY; Cox, JD; Fossella, F; Guerrero, T; Jeter, M; Kies, M; Komaki, R; Liao, Z; Milas, L; Smith, CM; Yuan, C, 2005) |
| "Celecoxib (CE) is a novel drug, with high selectivity and affinity for COX-2 enzyme." | 2.71 | Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and other non-steroidal anti-inflammatory drugs. ( Cazzola, M; D'Amato, G; D'Amato, M; De Giglio, C; Liccardi, G; Manfredi, D; Piscitelli, E, 2005) |
| "Inflammation is a biological function which triggered after the mechanical tissue disruption or from the responses by the incidence of physical, chemical or biological negotiator in body." | 2.61 | Human disorders associated with inflammation and the evolving role of natural products to overcome. ( Kishore, N; Kumar, P; Shanker, K; Verma, AK, 2019) |
| "Treatment of Celecoxib decreased DON-induced translocation of Protein Kinase C isozymes (α,ε,γ), demonstrating the role of PKC in DON-mediated biochemical and molecular alterations responsible for its dermal toxicity." | 1.56 | Celecoxib reduces Deoxynivalenol induced proliferation, inflammation and protein kinase C translocation via modulating downstream targets in mouse skin. ( Chaturvedi, S; Dewangan, J; Divakar, A; Kumar, S; Mandal, P; Mishra, S; Rath, SK; Srivastava, S; Tripathi, A; Wahajuddin, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Kishore, N | 1 |
| Kumar, P | 1 |
| Shanker, K | 1 |
| Verma, AK | 1 |
| Mishra, S | 1 |
| Srivastava, S | 1 |
| Divakar, A | 1 |
| Mandal, P | 1 |
| Dewangan, J | 1 |
| Chaturvedi, S | 1 |
| Wahajuddin, M | 1 |
| Kumar, S | 1 |
| Tripathi, A | 1 |
| Rath, SK | 1 |
| Wormser, U | 1 |
| Langenbach, R | 1 |
| Peddada, S | 1 |
| Sintov, A | 1 |
| Brodsky, B | 1 |
| Nyska, A | 1 |
| Liao, Z | 1 |
| Komaki, R | 1 |
| Milas, L | 1 |
| Yuan, C | 1 |
| Kies, M | 1 |
| Chang, JY | 1 |
| Jeter, M | 1 |
| Guerrero, T | 1 |
| Blumenschien, G | 1 |
| Smith, CM | 1 |
| Fossella, F | 1 |
| Brown, B | 1 |
| Cox, JD | 1 |
| Liccardi, G | 1 |
| Cazzola, M | 1 |
| De Giglio, C | 1 |
| Manfredi, D | 1 |
| Piscitelli, E | 1 |
| D'Amato, M | 1 |
| D'Amato, G | 1 |
| Weisberg, NK | 1 |
| Becker, D | 1 |
2 reviews available for celecoxib and Dermatoses
| Article | Year |
|---|---|
Human disorders associated with inflammation and the evolving role of natural products to overcome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Biological Products; Cardiovascular | 2019 |
Potential role of the new specific COX-2 inhibitors in dermatologic surgery.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Pain | 2000 |
2 trials available for celecoxib and Dermatoses
| Article | Year |
|---|---|
A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Combined | 2005 |
Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and other non-steroidal anti-inflammatory drugs.
Topics: Acetaminophen; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase | 2005 |
2 other studies available for celecoxib and Dermatoses
| Article | Year |
|---|---|
Celecoxib reduces Deoxynivalenol induced proliferation, inflammation and protein kinase C translocation via modulating downstream targets in mouse skin.
Topics: Animals; Celecoxib; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Infla | 2020 |
Reduced sulfur mustard-induced skin toxicity in cyclooxygenase-2 knockout and celecoxib-treated mice.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase | 2004 |